Next Article in Journal
Role of Transglutaminase 2 in Migration of Tumor Cells and How Mouse Models Fit
Next Article in Special Issue
Gut–Liver Axis: How Do Gut Bacteria Influence the Liver?
Previous Article in Journal
Lung Transplantation in Idiopathic Pulmonary Fibrosis
Previous Article in Special Issue
Gut Microbiota and Mucosal Immunity in the Neonate
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessReview
Med. Sci. 2018, 6(3), 69;

The Gut Microbiome in Multiple Sclerosis: A Potential Therapeutic Avenue

Department of Biology, Eastern Washington University, 258 Science Building, Cheney, WA 99004, USA
Author to whom correspondence should be addressed.
Received: 14 June 2018 / Revised: 27 July 2018 / Accepted: 22 August 2018 / Published: 24 August 2018
(This article belongs to the Special Issue Therapeutic Potential of the Microbiome)
Full-Text   |   PDF [816 KB, uploaded 24 August 2018]   |  


Recently, there has been a substantial increase in the number of studies focused upon connecting the gut microbiome with cases of central nervous system (CNS) autoimmunity. Multiple sclerosis (MS) is a neurodegenerative autoimmune disorder of the CNS. Recent experimental and clinical evidence suggests the presence of microbial imbalances in the gut of MS sufferers. The gut microbiome is defined as the summation of all the microbial entities as well as their genes, proteins, and metabolic products in a given space and time. Studies show the MS gut microbiome as having general alterations in specific taxa, some associated with the promotion of inflammatory cytokines and overall inflammation. In conjunction with these findings, experimental models of the disease have reported that T regulatory (Treg) cells have deficits in their function as a result of the aberrant gut microbiota composition. The findings suggest that the interactions between the host and the microbiota are reciprocal, although more extensive work is required to confirm this. Moreover, evidence indicates that changes in microbiota composition may result in imbalances that could result in disease, with the gut as a potential novel therapeutic avenue. By understanding the biological effects of aberrant gut microbiome composition, it is possible to contemplate current therapeutic options and their efficacy. Ultimately, more research is necessary in this field, but targeting the gut microbiota may lead to the development of novel therapeutic strategies. View Full-Text
Keywords: multiple sclerosis; microbiome; therapeutics; experimental autoimmune encephalomyelitis (EAE); animal models multiple sclerosis; microbiome; therapeutics; experimental autoimmune encephalomyelitis (EAE); animal models

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Kirby, T.O.; Ochoa-Repáraz, J. The Gut Microbiome in Multiple Sclerosis: A Potential Therapeutic Avenue. Med. Sci. 2018, 6, 69.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Med. Sci. EISSN 2076-3271 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top